| Anna Marie Sonstegard, MD | |
|
1310 W 22nd St, Sioux Falls, SD 57105-1501 | |
| (605) 328-6585 | |
| Not Available |
| Full Name | Anna Marie Sonstegard |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 7 Years |
| Location | 1310 W 22nd St, Sioux Falls, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902337298 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 01013321 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Usd Medical Center | Sioux falls, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center | 8325950215 | 707 |
News Archive
One of yesterday's most promising new tools for speeding the development of new medicines - "microdosing" - has found niches in that process today, and they include uses unanticipated a decade ago.
Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children's Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the U.S. Food and Drug Administration Office of Orphan Products Development.
According to a new study published on November 12, 2019, in the journal Molecular Psychiatry, individuals with schizophrenia resistant to treatment are more likely to have a family history and a lower IQ compared to other schizophrenic patients. This finding could help design more effective therapies for this subgroup of patients, as for instance, drugs that improve mental processes.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 9 days ago
| Entity Name | Sanford Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396764254 PECOS PAC ID: 0244143824 Enrollment ID: O20031110000532 |
News Archive
One of yesterday's most promising new tools for speeding the development of new medicines - "microdosing" - has found niches in that process today, and they include uses unanticipated a decade ago.
Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children's Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the U.S. Food and Drug Administration Office of Orphan Products Development.
According to a new study published on November 12, 2019, in the journal Molecular Psychiatry, individuals with schizophrenia resistant to treatment are more likely to have a family history and a lower IQ compared to other schizophrenic patients. This finding could help design more effective therapies for this subgroup of patients, as for instance, drugs that improve mental processes.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 9 days ago
| Entity Name | Sanford Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821017880 PECOS PAC ID: 8325950215 Enrollment ID: O20040115000388 |
News Archive
One of yesterday's most promising new tools for speeding the development of new medicines - "microdosing" - has found niches in that process today, and they include uses unanticipated a decade ago.
Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children's Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the U.S. Food and Drug Administration Office of Orphan Products Development.
According to a new study published on November 12, 2019, in the journal Molecular Psychiatry, individuals with schizophrenia resistant to treatment are more likely to have a family history and a lower IQ compared to other schizophrenic patients. This finding could help design more effective therapies for this subgroup of patients, as for instance, drugs that improve mental processes.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna Marie Sonstegard, MD Po Box 5074, Sioux Falls, SD 57117-5074 Ph: (605) 312-2373 | Anna Marie Sonstegard, MD 1310 W 22nd St, Sioux Falls, SD 57105-1501 Ph: (605) 328-6585 |
News Archive
One of yesterday's most promising new tools for speeding the development of new medicines - "microdosing" - has found niches in that process today, and they include uses unanticipated a decade ago.
Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children's Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the U.S. Food and Drug Administration Office of Orphan Products Development.
According to a new study published on November 12, 2019, in the journal Molecular Psychiatry, individuals with schizophrenia resistant to treatment are more likely to have a family history and a lower IQ compared to other schizophrenic patients. This finding could help design more effective therapies for this subgroup of patients, as for instance, drugs that improve mental processes.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 9 days ago
Dr. Jocelyn June Frohm, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1310 W 22nd St, Sioux Falls, SD 57105 Phone: 605-328-8600 Fax: 605-328-8601 | |
Lainee Goettsche, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6701 S Minnesota Ave, Sioux Falls, SD 57108 Phone: 605-322-6960 Fax: 605-322-6961 | |
Anna Brook Bahnson, MD Dermatology Medicare: Medicare Enrolled Practice Location: 6701 S Minnesota Ave, Sioux Falls, SD 57108 Phone: 605-322-6960 Fax: 605-322-6961 | |
Rachel Samuelson, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1400 W 22nd St, Sioux Falls, SD 57105 Phone: 605-357-1380 | |
Sarah Christine Kerr, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1310 W 22nd St, Sioux Falls, SD 57105 Phone: 605-328-8600 | |
Jana B Johnson, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6701 S Minnesota Ave, Sioux Falls, SD 57108 Phone: 605-322-6960 Fax: 605-322-6961 | |
Dr. Marcus Lee Frohm, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1310 W 22nd St, Sioux Falls, SD 57105 Phone: 605-328-8600 Fax: 605-328-8601 |